Patent intelligence · US
US 7619005
Methods for treating cognitive impairment in humans with Multiple Sclerosis
Methods for treating cognitive impairment in humans with Multiple Sclerosis
Patent details — US 7619005
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 17, 2009
- Expiration
- Nov 12, 2029
- Applicant
- Cognition Pharmaceuticals, LLC
- Claims
- 8
- CPC classes
- A61K, A61K31/137, A61K31/4458
Quick answer
US 7619005 (Methods for treating cognitive impairment in humans with Multiple Sclerosis) is held by Cognition Pharmaceuticals, LLC. Status: granted. Granted Nov 17, 2009. Expires Nov 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cognition Pharmaceuticals, LLC
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/137, A61K31/4458
More from Cognition Pharmaceuticals, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12208167
Coated tablets for pH-dependent release of benzgalantamine
granted -
US 12157743
Solid forms of Alpha-1062 gluconate
granted -
US 11795176
Solid forms of Alpha-1062 gluconate
granted -
US 11123351
Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
granted -
US 10603326
Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime
granted -
US 10351589
3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders
granted -
US 10342804
Steroid compound for use in the treatment of hepatic encephalopathy
granted -
US 10278977
Methods for treating hypersomnolence
granted
Frequently asked questions
What is US patent 7619005?
US 7619005 (Methods for treating cognitive impairment in humans with Multiple Sclerosis) is held by Cognition Pharmaceuticals, LLC. Status: granted. Granted Nov 17, 2009. Expires Nov 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7619005?
Cognition Pharmaceuticals, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 7619005 expire?
Our index shows an expiration date of Nov 12, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.